Allogene Therapeutics announced that its chief medical officer, Zachary Roberts, will succeed David Chang as president and CEO on July 1, with Roberts joining the board while Chang remains on the board after stepping down. The transition follows an eight-year period in which Chang led the off-the-shelf cell therapy company through multiple clinical and strategic phases. The appointment signals continuity in R&D leadership as Allogene navigates next-stage development decisions and prepares for operational changes tied to leadership handover.